T0	KEYPHRASE-NOTYPES 8 15	January,"een","200"
T1	KEYPHRASE-NOTYPES 25 30	April,"and","200"
T2	KEYPHRASE-NOTYPES 37 55	healthy volunteers,"04,","(co"
T3	KEYPHRASE-NOTYPES 57 65	controls,"rs "," an"
T4	KEYPHRASE-NOTYPES 71 82	individuals,"and","wit"
T5	KEYPHRASE-NOTYPES 90 97	history,"h a","of "
T6	KEYPHRASE-NOTYPES 101 113	Lyme disease," of","(pa"
T7	KEYPHRASE-NOTYPES 115 123	patients,"se "," be"
T8	KEYPHRASE-NOTYPES 137 141	ages,"the","of "
T9	KEYPHRASE-NOTYPES 155 160	years," 65","wer"
T10	KEYPHRASE-NOTYPES 177 198	follow-up evaluations,"ed;","wer"
T11	KEYPHRASE-NOTYPES 217 222	April," by","200"
T12	KEYPHRASE-NOTYPES 233 260	institutional review boards,"The","at "
T13	KEYPHRASE-NOTYPES 264 283	Columbia University," at","and"
T14	KEYPHRASE-NOTYPES 292 328	New York State Psychiatric Institute,"the","app"
T15	KEYPHRASE-NOTYPES 342 347	study,"the"," an"
T16	KEYPHRASE-NOTYPES 357 369	participants,"all","pro"
T17	KEYPHRASE-NOTYPES 396 403	consent,"med"," Ev"
T18	KEYPHRASE-NOTYPES 405 416	Evaluations,"nt.","wer"
T19	KEYPHRASE-NOTYPES 439 475	New York State Psychiatric Institute,"the","and"
T20	KEYPHRASE-NOTYPES 480 514	Columbia University Medical Center,"and"," Tr"
T21	KEYPHRASE-NOTYPES 516 526	Treatments,"er.","wer"
T22	KEYPHRASE-NOTYPES 550 557	patient,"ach","s h"
T23	KEYPHRASE-NOTYPES 560 564	home,"tâ€™s"," Pa"
T24	KEYPHRASE-NOTYPES 566 574	Patients,"me.","met"
T25	KEYPHRASE-NOTYPES 593 601	criteria,"ing"," (1"
T26	KEYPHRASE-NOTYPES 607 614	history,"(1)","of "
T27	KEYPHRASE-NOTYPES 618 655	physician-documented erythema migrans," of","or "
T28	KEYPHRASE-NOTYPES 659 671	U.S. Centers," or","for"
T29	KEYPHRASE-NOTYPES 676 691	Disease Control,"for","and"
T30	KEYPHRASE-NOTYPES 696 706	Prevention,"and","(CD"
T31	KEYPHRASE-NOTYPES 708 711	CDC,"on ","-de"
T32	KEYPHRASE-NOTYPES 721 734	manifestation,"ned","of "
T33	KEYPHRASE-NOTYPES 738 750	Lyme disease," of"," an"
T34	KEYPHRASE-NOTYPES 770 785	equivocal ELISA," or","con"
T35	KEYPHRASE-NOTYPES 799 830	positive Western blot serology6," by","7; "
T36	KEYPHRASE-NOTYPES 838 871	current positive IgG Western blot,"(2)","usi"
T37	KEYPHRASE-NOTYPES 878 903	CDC surveillance criteria,"ing"," as"
T38	KEYPHRASE-NOTYPES 922 949	single reference laboratory,"g a","(Un"
T39	KEYPHRASE-NOTYPES 951 970	University Hospital,"ry ","of "
T40	KEYPHRASE-NOTYPES 974 985	Stony Brook," of","; ("
T41	KEYPHRASE-NOTYPES 992 1001	treatment,"(3)","for"
T42	KEYPHRASE-NOTYPES 1006 1018	Lyme disease,"for","wit"
T43	KEYPHRASE-NOTYPES 1035 1040	weeks,"t 3","of "
T44	KEYPHRASE-NOTYPES 1047 1058	ceftriaxone," IV"," co"
T45	KEYPHRASE-NOTYPES 1081 1087	months,"t 4","bef"
T46	KEYPHRASE-NOTYPES 1095 1106	study entry,"ore"," (4"
T47	KEYPHRASE-NOTYPES 1112 1140	subjective memory impairment,"(4)","tha"
T48	KEYPHRASE-NOTYPES 1150 1168	participant report," by"," st"
T49	KEYPHRASE-NOTYPES 1188 1193	onset,"the","of "
T50	KEYPHRASE-NOTYPES 1197 1209	Lyme disease," of"," an"
T51	KEYPHRASE-NOTYPES 1219 1237	objective evidence,"(5)","of "
T52	KEYPHRASE-NOTYPES 1241 1258	memory impairment," of","as "
T53	KEYPHRASE-NOTYPES 1280 1306	Wechsler Memory Scale III8,"the","com"
T54	KEYPHRASE-NOTYPES 1321 1324	age,"ith",", s"
T55	KEYPHRASE-NOTYPES 1327 1330	sex,"e-,",", a"
T56	KEYPHRASE-NOTYPES 1337 1372	education-adjusted population norms,"and"," Th"
T57	KEYPHRASE-NOTYPES 1380 1394	study criteria,"ese","wer"
T58	KEYPHRASE-NOTYPES 1435 1456	diagnostic confidence,"nce"," Pr"
T59	KEYPHRASE-NOTYPES 1467 1485	antibiotic therapy," IV","was"
T60	KEYPHRASE-NOTYPES 1518 1526	patients,"all","had"
T61	KEYPHRASE-NOTYPES 1540 1549	treatment,"ved","con"
T62	KEYPHRASE-NOTYPES 1574 1597	neurologic Lyme disease,"for","by "
T63	KEYPHRASE-NOTYPES 1611 1621	guidelines,"hed"," [9"
